S&P Futures
5,888.75 -3.75 (-0.06%) Dow Futures
43,047.00 -122.00 (-0.28%) Nasdaq Futures
20,521.75 -20.25 (-0.10%) Russell 2000 Futures
2,244.70 -1.50 (-0.07%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,753.40 -6.40 (-0.23%)
Teva Pharmaceutical Industries Limited (TEVJF)
- Insider Monkey
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Kontra Investment Xchange’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited’s share was trading at $17.95 as of Oct 18th. TEVA’s trailing and forward P/E were 872 and 6.78 respectively according to Yahoo Finance. […]
- GlobeNewswire
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitisThe FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024SELARSDI’s U.S. launch for all indications is expected in Q1 2025 REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.
